When colorectal cancer (CRC) spreads to the lining of the abdomen (the peritoneum), treatment becomes more complex. For some patients with metastatic colorectal cancer (mCRC) involving the peritoneum, cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) may be considered as part of treatment.
Research has helped establish CRS as a potential option for carefully selected patients, particularly when surgeons are able to remove all visible disease. There is ongoing debate, however, about the added benefit of HIPEC, and experts continue to study which patients may benefit most from including it as part of treatment.
Because CRS-HIPEC is an intensive procedure with significant risks and a long recovery, treatment decisions are highly individualized and typically made at experienced cancer centers with multidisciplinary teams. Here’s what to know about how the procedure works and who may be considered for treatment.
The two-step process: How CRS and HIPEC work together
CRS and HIPEC for mCRC is a sequenced, two-phase procedure designed to eliminate both visible and microscopic cancer cells.
Phase 1: Cytoreductive surgery (CRS)
The surgical team removes all visible tumor nodules from the peritoneal lining and affected organs. This may include removing portions of the bowel or other structures. The primary goal is “complete cytoreduction,” leaving no visible disease behind.
Phase 2: HIPEC (the “chemo bath”)
Once the visible tumors are removed, a heated chemotherapy solution circulates through the abdominal cavity. This targeted delivery allows for much higher drug concentrations than systemic IV chemotherapy, as the heat helps the drugs penetrate microscopic cancer cells that the surgeon can’t see.
Genetic markers and eligibility
Eligibility for CRS with or without HIPEC is based on several clinical factors. Important considerations include:
- Whether surgeons believe all visible disease can be safely removed
- The extent of peritoneal disease, often measured using the Peritoneal Cancer Index (PCI)
- Whether the cancer has spread outside the abdomen
- Overall health and ability to tolerate a major operation
- Response to prior systemic therapy
Researchers are continuing to study how tumor biology and biomarkers may influence outcomes after CRS with or without HIPEC for mCRC with peritoneal metastases. While certain mutations have been linked to differences in prognosis in some studies, more data is needed to understand the connection.
At this time, biomarkers such as BRAF, RAS (KRAS/NRAS), and MSI-H/dMMR aren’t considered standalone criteria for determining who should or shouldn’t receive CRS-HIPEC. Instead, treatment decisions are primarily based on factors such as the extent of peritoneal disease, whether surgeons believe a complete cytoreduction can be achieved, the presence of disease outside the abdomen, and a patient’s overall health and ability to recover from major surgery.
Because patient selection is complex, evaluation at an experienced multidisciplinary cancer center is important.
Is there value in HIPEC after surgery?
CRS plays an important role in carefully selected patients with colorectal peritoneal metastases, particularly when surgeons can achieve a complete cytoreduction. The ongoing debate is less about the value of CRS itself and more about whether adding HIPEC provides additional benefit beyond surgery alone.
Much of this discussion stems from the phase III PRODIGE 7 trial, which compared CRS alone with CRS plus oxaliplatin-based HIPEC in patients with colorectal peritoneal metastases. The study found no significant improvement in overall survival when HIPEC was added to surgery. However, both groups in the trial underwent extensive CRS, and the overall survival outcomes seen in the study reinforced the importance of achieving complete cytoreduction at specialized centers.
Since the publication of PRODIGE 7, experts have continued to debate several unresolved questions, including:
- Whether the specific HIPEC regimen used in the trial (short-duration oxaliplatin) affected the results
- Whether certain subgroups of patients may benefit more than others
- Whether alternative HIPEC drugs, durations, or treatment protocols could produce different outcomes
- How newer systemic therapies and molecular profiling may influence patient selection
Because of these unanswered questions, practices vary between cancer centers. Some institutions continue to use HIPEC selectively in addition to CRS, while others focus primarily on surgery and systemic therapy. For patients, this means the conversation is often not simply “Should I get HIPEC?” but rather:
- Am I a candidate for complete cytoreductive surgery?
- Would adding HIPEC meaningfully improve outcomes in my specific situation?
- What are the potential benefits compared with the added risks and recovery time?
These are nuanced decisions that are best discussed with a multidisciplinary care team experienced in treating colorectal peritoneal metastases.
Risks of HIPEC surgery and recovery
As KU Cancer Center notes, CRS-HIPEC combines the dual physical demands of major abdominal surgery and internal chemotherapy. Recovery isn’t measured in days, it’s measured in months.
Here’s a transparent look at what patients typically face:
Short-term risks | Long-term recovery goals |
Bowel complications (ileus, leakage) | Restoring normal digestive function |
Wound infection or sepsis | Rebuilding physical strength and stamina |
Blood clots and fluid imbalances | Returning to meaningful daily activities |
Cognitive fog (“chemo brain”) | Sustained nutritional health and weight stability |
Prolonged ICU or hospital stay (2–4 weeks typical) | Monitoring for recurrence with regular imaging |
The surgical procedure itself runs 8–12 hours. That physical toll is significant, even for well-selected patients. Most people spend several days in the ICU before transferring to a general ward, and full functional recovery can take three to six months.
Understanding life expectancy after HIPEC requires looking beyond the operating table. Outcomes depend heavily on how well complications are managed and how actively patients engage in post-operative rehabilitation. Quality of life does improve meaningfully for many patients over time, though the path there demands realistic expectations and strong support systems.
Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.
